A pivotal phase IIb/III trial of WT1 vaccine in patients with malignant pleural mesothelioma
Phase of Trial: Phase II/III
Latest Information Update: 14 Sep 2016
At a glance
- Drugs Galinpepimut S (Primary)
- Indications Mesothelioma
- Focus Registrational; Therapeutic Use
- Sponsors Sellas Life Sciences Group
- 14 Sep 2016 According to Sellas Life Sciences Group media release, this trial is expected to start in early 2017.
- 14 Sep 2016 Planned initiation date changed from 1 Jul 2016 to 1 Jan 2017, as per Sellas Life Sciences Group media release.
- 29 Mar 2016 According to SELLAS Life Sciences media release, based on results of phase II trial (see CTP 700192768), the company plans to initiate this pivotal trial of WT1 peptide vaccine in patients with MPM, in the third quarter of 2016.